Citadel Advisors’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Citadel Advisors’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,182	Closed	-$14.4K	–	15622
2023 Q4	$14.4K	Buy	+1,182	New	+$27.7K	﹤0.01%	12878
2022 Q4	–	Sell	-478	Closed	-$362K	–	15580
2022 Q3	$362K	Buy	+478	New	+$153K	﹤0.01%	9171
2022 Q2	–	Sell	-105	Closed	-$57K	–	14334
2022 Q1	$57K	Buy	105 +83	+377%	+$62K	﹤0.01%	12709
2021 Q4	$22K	Sell	22 -2	-8%	-$2.89K	﹤0.01%	13568
2021 Q3	$41K	Buy	+24	New	+$49.6K	﹤0.01%	13466

Other funds holding ATXI

Sabby Management Miami Beach, Florida $9.02M AUM 74.48% 1-Year Est. Return

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citadel Advisors's ATXI Position: Q1 2024 in Review

Citadel Advisors sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2024, closing a stake of 1,182 shares — an estimated $14.4K sold.

Citadel Advisors first reported a position in ATXI in Q3 2021 and held it in 5 quarters. The position peaked at $362K in Q3 2022. 13 funds tracked by Wall St. Rank hold ATXI as of Q1 2024.

Citadel Advisors reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 1,182 Avenue Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $14.4K.
Citadel Advisors first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
Citadel Advisors's Avenue Therapeutics, Inc. Common Stock position peaked at $362K in Q3 2022.
13 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.